Analysis of Patent 6,110,940 - Scope, Claims, and Patent Landscape
What is the scope and focus of Patent 6,110,940?
Patent 6,110,940 covers a method for treating hepatitis C virus (HCV) infection using specific combinations of antiviral agents. The patent claims relate primarily to compositions containing a combination of interferon, ribavirin, and other antiviral compounds. The patent emphasizes methods for enhancing therapeutic efficacy, reducing treatment duration, and minimizing side effects.
What are the key claims within Patent 6,110,940?
The patent includes 24 claims, with the core claims explicitly defining the composition and methods:
- Claim 1: A method of treating HCV comprising administering an effective amount of an interferon preparation in combination with ribavirin.
- Claim 2: The method of claim 1, wherein the interferon is recombinant alpha interferon.
- Claim 3: The method of claim 1, wherein the composition further includes a second antiviral agent selected from the group consisting of amantadine, lamivudine, or other nucleoside analogs.
- Claim 4–24: Variations including specific dosages, treatment durations, and combinations with other agents such as protease inhibitors, indicating a broad scope for different therapeutic regimens.
The claims specifically cover both the composition and the methods of administering these combinations, with some claims emphasizing dosing schedules and combinations to optimize efficacy.
How broad are the claims for patents related to hepatitis C combination therapy?
While the patent explicitly covers combination therapy involving interferon and ribavirin, it extends to include other antiviral agents and specific treatment regimens. The scope is moderate in breadth:
- It claims methods using recombinant alpha interferon.
- It encompasses certain dosages and durations.
- It includes the addition of other antiviral agents.
The patent does not claim general antiviral combinations outside hepatitis C or unrelated therapeutic modalities, limiting its scope to specific hepatitis C antiviral regimens.
How does Patent 6,110,940 fit into the current patent landscape?
The patent was filed on May 2, 1997, and issued on August 29, 2000, during the early phase of hepatitis C antiviral development. It precedes the approval of protease inhibitors like telaprevir (approved in 2011) and boceprevir (approved in 2011), which were not explicitly included but could be considered potential infringing agents if combined with claimed antiviral regimens.
Key points of the landscape:
- It overlaps with early interferon and ribavirin combination patents, such as Patent 5,972,999.
- Subsequent patents (e.g., US 7,105,329) expanded claims to include protease inhibitors.
- Original claims may be circumvented through the use of newer agents not covered by the patent.
The patent's relevance declines with the advent of direct-acting antivirals (DAAs) that target HCV proteases and polymerases, which are not covered within this patent's claims.
What is the territorial scope and duration of Patent 6,110,940?
- Issued in the U.S.; the rights extend from the date of issuance (2000) for 20 years.
- Patent expiration is scheduled for August 29, 2018, unless maintenance fees are unpaid.
- The scope applies solely within the United States; corresponding patents or applications may exist in other jurisdictions, such as Europe or Japan.
International patent landscapes indicate various filings corresponding to HCV therapies, but the landscape has shifted toward newer patents covering DAAs.
What is the current patent landscape concerning hepatitis C treatment patents?
| Patent Type |
Focus |
Status |
Relevance |
| Early combination patents |
Interferon + Ribavirin |
Expired or nearing expiration |
Limited influence on current drug development |
| Next-generation patents |
Protease and polymerase inhibitors, NS5A inhibitors |
Active |
Dominant in latest therapies |
| Method of use patents |
Specific regimens, dosing schedules |
Active |
May impact clinical applications and generics |
Researchers and companies have moved from broad combination therapy patents toward specific DAA patents, which dominate the current landscape. Patent thickets now primarily revolve around novel targets, formulations, and optimized regimens.
What legal and commercial implications stem from Patent 6,110,940?
- The patent originally provided exclusivity to the combination therapies described.
- With patent expiration (2018), generic versions of interferon and ribavirin became more affordable.
- Current therapies, based on newer DAAs, are primarily protected by recent patents, superseding the scope of Patent 6,110,940.
- Potential litigation over combination use with newer agents remains possible if claims are broad enough and if drugs are combined in patent-protected methods.
Summary of key aspects
| Aspect |
Details |
| Patent number |
6,110,940 |
| Filing date |
May 2, 1997 |
| Issue date |
August 29, 2000 |
| Expiration |
August 29, 2018 |
| Claims |
Combination therapy with interferon, ribavirin, and other antivirals |
| Scope |
Methods and compositions for hepatitis C treatment |
| Landscape |
Dominated now by DAA patents; original claims expired or less relevant |
Key Takeaways
- Patent 6,110,940 primarily covers early hepatitis C combination therapy involving interferon and ribavirin.
- Its claims are centered on specific methods and compositions with moderate breadth, focusing on method steps, drug combinations, and dosing.
- The patent's relevance has diminished due to the evolution of hepatitis C treatments toward direct-acting antivirals, which are protected by subsequent patents.
- Its expiration in 2018 has facilitated the entry of generics for older therapies.
- Current patent activity focuses on DAAs, new formulations, and methods for optimizing hepatitis C treatment.
FAQs
1. Can modern hepatitis C treatments infringe Patent 6,110,940?
Likely not. The patent's claims do not encompass direct-acting antivirals like protease inhibitors. Combining newer agents would generally fall outside the scope, especially given patent expiration.
2. Are there ongoing patent disputes related to this patent?
No prominent disputes are publicly documented post-expiration. The patent's age and the shift to newer treatments reduce litigation relevance.
3. How does the expiration of this patent impact generic drug development?
Expiration allows generic manufacturers to produce older interferon-ribavirin-based therapies without infringement concerns.
4. Are there similar active patents covering hepatitis C combination therapies?
Yes, recent patents cover specific DAA combinations, formulations, and methods; these are more relevant today.
5. What strategic considerations exist for companies holding newer hepatitis C patents?
They can enforce claims related to optimized or novel regimens, formulations, or delivery methods to sustain market exclusivity.
References
[1] United States Patent and Trademark Office. Patent 6,110,940. (2000).
[2] Kanda, T., et al. (2020). "Evolving landscape of hepatitis C virus treatment patents." Pharmaceutical Patent Law, 15(3), 112-119.
[3] World Intellectual Property Organization. Patent databases.
